The World Medical Innovation Forum, hosted by Partner HealthCare, is a global gathering of more than 1,000 senior health care leaders in the heart of Boston. It was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together to improve patient lives. The World Medical Innovation Forum focuses on the advancements and opportunities of Artificial Intelligence.
This year’s event will bring together industry-leading CEOs, Partners’ HIT experts, investor and deal makers as they share perspectives on how cognitive computation, machine learning, and big data are having a transformative impact on patient care. International experts will be joined by attendees from the senior ranks of the information technology, life science, pharmaceutical, government and health care investment communities, as well as top Partners HealthCare, Brigham and Women’s Hospital, Massachusetts General Hospital, Spaulding Hospital and McLean Hospital faculty and staff.
Read more here.
Tero-Pekka Alastalo, co-founder and Chief Medical Officer of Blueprint Genetics will be leading a talk “Validating and optimizing NGS-based diagnostics to improve diagnostic yield and clinical utility” on April 26th 12:40 pm – 1:00 pm.
Topics covered will include:
- Challenges in the field of genetic diagnostics and current technologies used to address them
- Introducing the concept and importance of transparent, traceable, and comprehensive analytic validation of an NGS platform for clinical diagnostics
- Patient examples which demonstrate the importance of high quality and comprehensive genetic diagnostics for improved outcomes for rare disease patients
- Controlling costs by utilizing high quality WES derived sequencing data for rare disease patients